TOLLYS
Tollys is a biopharmaceutical company focused on innate immunity, particularly on the biology and modulation of the TLR3 receptor. The company is advancing TL-532, a new cancer immunotherapy to treat various types of cancer. TL-532 is a structurally defined double-stranded RNA, produced synthetically and highly specific to the TLR3 receptor.
TOLLYS
Industry:
Biopharma Biotechnology Pharmaceutical
Founded:
2015-01-01
Address:
Lyon, Rhone-Alpes, France
Country:
France
Website Url:
http://www.tollys.fr
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
2.3 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Apache Wordpress Plugins Mobile Non Scaleable Content
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Imvax
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
Current Advisors List
Current Employees Featured
Founder
Investors List
Investisseurs privés
Investisseurs privés investment in Series A - Tollys
Official Site Inspections
http://www.tollys.fr
- Host name: 217-160-0-162.elastic-ssl.ui-r.com
- IP address: 217.160.0.162
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
Loading ... 